

## Natco Pharma Limited

Regd. Off: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034, INDIA Tel: +91 40 23547532, Fax: +91 40 23548243

Email: <u>info@natcopharma.co.in</u> **CERTIFICATE OF ANALYSIS** 

Product Name: Sofokast Tablets		B.No.: 1901146
Generic Name: Sofosbuvir 400 m	g Tablets	Product Code: GSF41AZ
Batch size: 90969 Tablets	Sampling Date: 25/02/2019	Mfg. Date: 02/2019
Qty. Sampled: 01 Container	Analysis Date: 25/02/2019	Exp. Date: 01/2021
Sampled by: Priyanka	Reporting Date: 28/02/2019	A.R. No.: FP/AR/076/19

S.No	TEST	SPECIFICATION	RESULT
1.	Description	Brick red coloured, capsule shaped, film coated tablets debossed with '400' on one side and plain on other side.	Brick red coloured, capsule shaped, film coated tablets debossed with '400' on one side and plain on other side.
2.	Identification a) By HPLC  b) By UV	The retention time of the major peak in the chromatogram of the sample preparation should correspond to that in the chromatogram of the standard preparation, as obtained in the Assay.  The UV absorption spectrum of the sample solution and	The retention time of the major peak in the chromatogram of the sample preparation corresponds to that in the chromatogram of the standard preparation, as obtained in the Assay.  The UV absorption spectrum of the sample solution and standard solution exhibits maxima at the
	4	standard solution shall exhibit maxima at the same wavelengths.	same wavelengths.
3.	Uniformity of dosage units (By weight variation)	The acceptance value of the first 10 dosage units is less than or equal to L1 (L1 is 15.0 and L2 is 25.0)	Acceptance value = 2.66

	PREPARED BY	CHECKED BY	APPROVED BY
Sign	Chiples 12019	RA 01/03/2019	Dhundran
Name	BN Retauri	Rustam Alam	Sanjay-S. Charaboos
Designation	Ofto an-elc	obtion oc.	So manager ell

Format No.: QCS/004/F04-02

Page No: 1 of 3



## Natco Pharma Limited

Regd. Off: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034, INDIA Tel: +91 40 23547532, Fax: +91 40 23548243

Email: info@natcopharma.co.in
CERTIFICATE OF ANALYSIS

D. 1 AVALISIS			
Product Name: Sofokast Tablets		B.No.: 1901146	
Generic Name: Sofosbuvir 400 mg Tablets		Product Code: GSF41AZ	
Batch size: 90969 Tablets	Sampling Date: 25/02/2019	Mfg. Date: 02/2019	
Qty. Sampled: 01 Container	Analysis Date: 25/02/2019	Exp. Date: 01/2021	
Sampled by: Priyanka	Reporting Date: 28/02/2019	A.R. No.: FP/AR/076/19	

S.No	TEST	SPECIFICATION	RESULT
4.	Average weight per tablet	1236.0 mg ± 3.0 %	1241.00 mg
5.	Water content (By KF)	Not more than 4.0% w/w	1.89 % w/w
6.	Dissolution (By UV)	Not less than 80% (Q) of the labeled amount of Sofosbuvir is dissolved in 30 minutes.	Minimum = 99.9 % Maximum = 101.7 % Average = 101.0 %
7.	Assay (By HPLC) Each film coated tablet contains 400 mg of Sofosbuvir.	Not less than 90.0% and not more than 110.0% of the labeled amount of Sofosbuvir.	100.1 %
8.	Related impurities (By HPLC)		
	a) Individual unknown impurity	Not more than 0.5 %	0.02 %
	b)Total impurities	Not more than 2.0 %	0.04%

a.	PREPARED BY	CHECKED BY	APPROVED BY
Sign	Gelorpo 19	RA 0110312019	Shundai 2019
Name	BN Redwar	Rustam Alam	Sanjay, S. churchai
Designation	Ofticen-cec	obsier QC.	Sy mangeral

Format No.: QCS/004/F04-02

Page No: 2 of 3



## **Natco Pharma Limited**

Regd. Off: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 034, INDIA Tel: +91 40 23547532, Fax: +91 40 23548243

Email: info@natcopharma.co.in

## CERTIFICATE OF ANALYSIS

Product Name: Sofokast Tablets		B.No.: 1901146
Generic Name: Sofosbuvir 400 mg Tablets		Product Code: GSF41AZ
Batch size: 90969 Tablets Sampling Date: 25/02/2019		Mfg. Date: 02/2019
Qty. Sampled: 01 Container	Analysis Date: 25/02/2019	Exp. Date: 01/2021
Sampled by: Priyanka	Reporting Date: 28/02/2019	A.R. No.: FP/AR/076/19

S.No	TEST	SPECIFICATION	RESULT	
9.	. Microbial Enumeration tests & test for specified microorganisms USP <61> & <62>			
	Total aerobic microbial count	Not more than 1000 cfu/g	<10 cfu/g	
	Total combined molds and	Not more than 100 cfu/g	10.07	
	Yeasts		< 10 cfu/g	
	Escherichia coli	Should be absent/g	Absent	
	Salmonella species	Should be absent/10 g	Absent	
	Staphylococcus aureus	Should be absent/g	Absent	
,	Pseudomonas aeruginosa	Should be absent/g	Absent	

Remarks: The product complies as per Specification No.: FP/SPC/004-01

	PREPARED BY	CHECKED BY	APPROVED BY
Sign	28 Por 120 19	RA 01/03/2019	Shringhain 2019
Name	BN Patwari	Pastan Alan	Sanjay S- Charles
Designation	Ofticer-de	obficer & c.	Sy managerbal

Format No.: QCS/004/F04-02

Page No: 3 of 3